Antibody engineering for therapeutics
- 19 July 2003
- journal article
- review article
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 13 (4), 519-525
- https://doi.org/10.1016/s0959-440x(03)00103-9
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Monoclonal Antibody Therapy for CancerAnnual Review of Medicine, 2003
- Engineered antibodiesNature Medicine, 2003
- Therapeutic antibodies for human diseases at the dawn of the twenty-first centuryNature Reviews Drug Discovery, 2003
- Efficient carcinoma cell killing by activated polymorphonuclear neutrophils targeted with an Ep-CAM×CD64 (HEA125×197) bispecific antibodyCancer Immunology, Immunotherapy, 2002
- Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphomaBlood, 2002
- Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s LymphomaThe Journal of Immunology, 2002
- A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancerBritish Journal of Cancer, 2001
- Bispecific human IgG by designJournal of Immunological Methods, 2001
- Pharmacokinetic–pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neuJournal of Immunological Methods, 2001
- Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivoJournal of Immunological Methods, 2001